Search

Abstract & Case Report submission

Late-breaking case report submission is now closed.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2019

Dates: October 4-5, 2019
Location: Mendoza, Argentina
Chairs: 
Prof Dorotea Fantl, President, Sociedad Argentina de Hematología (SAH)
Prof Marivi Mateos, EHA Executive Board Member, European Hematology Association (EHA)

EHA, in partnership with the Sociedad Argentina de Hematología (SAH), is bringing the key messages from the…

Read more

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

EHA Innovation Grant

The call for applications is closed. The EHA Innovation Grant is intended to encourage and support the creation of consortia and the generation of preliminary data to facilitate applying for larger funding opportunities.

Read more

EHA Statement of Solidarity with Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Read more

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more